Elite Pharmaceuticals announced that the FDA has approved its supplemental new drug application (sNDA) for Naltrexone HCl Tablets, the generic of Teva‘s Revia.

Naltrexone HCl is an opioid receptor antagonist used primarily in the management of alcohol dependence and opioid addiction. Naltrexone HCl competitively binds to such receptors and may block the effects of endogenous opioids. Opioid antagonists have also been shown to reduce alcohol consumption in clinical studies.

Naltrexone HCl will be available in 50mg dosage strength tablets.

For more information call or visit www.elitepharma.com